Document Detail


Should degenerated saphenous vein grafts routinely be sealed with drug-eluting stents?
MedLine Citation:
PMID:  16336427     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The percutaneous treatment of patients with obstructive atherosclerotic disease in degenerated coronary saphenous vein bypass grafts still remains one of the great challenges in interventional cardiology. In this review, we discuss the actual evidence-based knowledge for the percutaneous management of this lesion subset, focusing in particular on the devices that are actually considered the "gold standard" for this treatment: bare metal stents and distal protection devices. We also comment on the negative results of the randomized trials regarding the promising polytetrafluoroethylene-covered stent-grafts. We finally offer insights into the currently available evidence for the use of drug-eluting stents in saphenous vein grafts. These devices are potentially the principal promise for the long-term successful sealing of vein graft disease; however, clear and definitive data coming from controlled trials are requested.
Authors:
Paul Vermeersch; Pierfrancesco Agostoni
Related Documents :
12515737 - Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative corona...
18585507 - Safety and effectiveness of drug-eluting stents among diabetic patients: a propensity a...
8752797 - Primary stent implantation without coumadin in acute myocardial infarction.
9398107 - Feasibility and applicability of coronary stent implantation with the direct brachial a...
9869527 - Comparison of ecg variables of dispersion of ventricular repolarization with direct myo...
23824697 - Pharmacological agents for preventing morbidity associated with the haemodynamic respon...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of interventional cardiology     Volume:  18     ISSN:  0896-4327     ISO Abbreviation:  J Interv Cardiol     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-12     Completed Date:  2006-02-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8907826     Medline TA:  J Interv Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  467-73     Citation Subset:  IM    
Copyright Information:
(J Interven Cardiol 2005;18:467-473).
Affiliation:
The Department of Cardiology, AZ Middelheim, Antwerp, Belgium. paul.vermeersch@zna.be
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Transluminal, Percutaneous Coronary*
Blood Vessel Prosthesis Implantation*
Coronary Artery Bypass
Coronary Artery Disease / therapy*
Coronary Restenosis / prevention & control
Drug Delivery Systems
Evidence-Based Medicine
Humans
Immunosuppressive Agents / administration & dosage
Saphenous Vein / pathology,  transplantation*
Sirolimus / administration & dosage
Stents*
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of unprotected left main coronary artery stenosis in the drug-eluting stent era.
Next Document:  Percutaneous saphenous vein graft interventions with and without distal filter wire protection.